<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488420</url>
  </required_header>
  <id_info>
    <org_study_id>MHICC-2017-001</org_study_id>
    <nct_id>NCT03488420</nct_id>
  </id_info>
  <brief_title>Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE</brief_title>
  <acronym>CAPTURE</acronym>
  <official_title>Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation and/or ATrial Flutter With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this registry is the characterization of patients with atrial fibrillation&#xD;
      (AF) and/ or atrial flutter (AFL) with confirmed VHD who are prescribed edoxaban in a real&#xD;
      life clinical setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, prospective, multicenter, edoxaban Canadian registry of adults&#xD;
      (≥18) diagnosed or confirmed with AF and/or AFL with VHD, within the last 12 months,&#xD;
      according to local standard procedures and judged by the investigator to be at risk of stroke&#xD;
      and in whom anticoagulation with NOAC is clinically indicated and who are prescribed&#xD;
      edoxaban. A total of about 300 patients will be enrolled from approximately 10 sites in&#xD;
      Quebec. Patients will be treated according to standard local practices. There is no formal&#xD;
      interventions. Treatment decisions are left to the physician's discretion.&#xD;
&#xD;
      Registry data will be collected by the investigator or delegate at baseline, 6, 12 and 24&#xD;
      months and recorded in the electronic Case Report Form (eCRF).&#xD;
&#xD;
      Data available in the patient's file will be collected. The only procedure to be performed in&#xD;
      the context of this registry is the completion of questionnaires: the Montreal Cognitive&#xD;
      Assessment (MoCA©) test and the Anti-Clot-Treatment Scale (ACTS-Q) questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Characterization of patients with diagnosed or confirmed atrial fibrillation (AF) and/or atrial flutter (AFL) with valvular heart disease (VHD), within the last 12 months</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient treatment satisfaction using Anti-Clot Treatment Scale (ACTS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function using the Montreal Cognitive Assessment (MoCA) test</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance of subjects to edoxaban treatment</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for choosing edoxaban and reasons for the dosage</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients on appropriate dosage of edoxaban (60 mg and 30 mg if dose reduction criteria)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke (hemorrhagic stroke, ischemic stroke), transient ischemic attack (TIA) and systemic embolism events (SEE)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding (Frequency, Location, Severity, Type of intervention and Outcome)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death (CV and non-CV)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs) and serious adverse events (SAEs) related to edoxaban</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician satisfaction with regards to edoxaban treatment</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atrial Fibrillation and Flutter</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>Atrial Fibrillation and/or Atrial Flutter</arm_group_label>
    <description>Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban Pill</intervention_name>
    <description>Subjects will be taking edoxaban 30 or 60 mg</description>
    <arm_group_label>Atrial Fibrillation and/or Atrial Flutter</arm_group_label>
    <other_name>Lixiana</other_name>
    <other_name>edoxaban tosylate monhydrate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient diagnosed or confirmed with Atrial Fibrillation (AF) and/or atrial flutter (AFL)&#xD;
        with valvular heart disease (VHD) within the last 12 months, according to local standard&#xD;
        procedures, judged by the investigator to be at risk of stroke and in whom anticoagulation&#xD;
        with a NOAC drugs is clinically indicated and who are prescribed edoxaban.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients aged ≥ 18 years at baseline (signing of consent);&#xD;
&#xD;
          2. Willing and able to provide written informed consent;&#xD;
&#xD;
          3. Patient diagnosed or confirmed with AF and/or AFL within the last 12 months of signed&#xD;
             consent form;&#xD;
&#xD;
          4. Patient with VHD confirmed by echocardiography within the last 36 months of signed&#xD;
             consent form except for mitral stenosis that must be confirmed within the last 12&#xD;
             months;&#xD;
&#xD;
          5. Patient at risk for stroke in whom a long term oral anticoagulation is indicated and&#xD;
             who are prescribed edoxaban.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with AF and/or AFL secondary to reversible cause;&#xD;
&#xD;
          2. Patients with a mechanical heart valve or rheumatic mitral stenosis, or moderate and&#xD;
             severe non rheumatic mitral stenosis;&#xD;
&#xD;
          3. Patients planned to have an intervention for valvular heart disease in the next 12&#xD;
             months;&#xD;
&#xD;
          4. Pregnant or breastfeeding women.&#xD;
&#xD;
          5. Short term anticoagulation post cardioversion or ablation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katia Dyrda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Cloutier, M. Sc.</last_name>
    <phone>514-461-1300</phone>
    <phone_ext>3581</phone_ext>
    <email>isabelle.cloutier@mhicc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Orfanos, MD</last_name>
    <phone>514-461-1300</phone>
    <phone_ext>3480</phone_ext>
    <email>andreas.orfanos@mhicc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie-CHUS-Centre Haute-Yamaska-hôpital de Granby</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Bourgeois, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CISSS de la Montérégie Centre</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Laflamme, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CISSS de Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Descarries, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katia Dyrda, MD</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>2408</phone_ext>
      <email>katia.dyrda@icm-mhi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Nault, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CISSS du Bas-Saint-Laurent/Hôpital Régional de Rimouski</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian Azzari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Roux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de la Mauricie-et-du-Centre-du-Québec</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Leite Vieira Costa, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

